Laurence Zitvogel
#33,380
Most Influential Person Now
French physician
Laurence Zitvogel's AcademicInfluence.com Rankings
Laurence Zitvogelbiology Degrees
Biology
#1621
World Rank
#2665
Historical Rank
Immunology
#55
World Rank
#61
Historical Rank
Laurence Zitvogelphilosophy Degrees
Philosophy
#2770
World Rank
#4635
Historical Rank
Logic
#776
World Rank
#1308
Historical Rank
Download Badge
Biology Philosophy
Laurence Zitvogel's Degrees
- Doctorate Medicine Paris Diderot University
- PhD Immunology Paris Diderot University
Why Is Laurence Zitvogel Influential?
(Suggest an Edit or Addition)According to Wikipedia, Laurence Zitvogel is a French physician specializing in oncology and immunology with a large research experience in exosomess and the biological impact of those structures in malignant neoplasms. Personal life Laurence Zitvogel was born in Suresnes, France on 25 December 1963. She has worked with her spouse, Guido Kroemer, since 2001.
Laurence Zitvogel's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Exosomes: composition, biogenesis and function (2002) (4283)
- Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 (2018) (3106)
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors (2018) (3049)
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy (2007) (2668)
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients (2018) (2594)
- Calreticulin exposure dictates the immunogenicity of cancer cell death (2007) (2495)
- Innate or Adaptive Immunity? The Example of Natural Killer Cells (2011) (2313)
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota (2015) (2213)
- Immunogenic cell death in cancer therapy. (2013) (2210)
- Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes (1998) (1996)
- Antigen presentation and T cell stimulation by dendritic cells. (2002) (1939)
- Immunogenic cell death in cancer and infectious disease (2016) (1609)
- Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors (2009) (1606)
- Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming (2001) (1422)
- The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide (2013) (1421)
- The immune contexture in cancer prognosis and treatment (2017) (1295)
- Cancer despite immunosurveillance: immunoselection and immunosubversion (2006) (1252)
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients (2007) (1181)
- Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity (1995) (1168)
- Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo (1999) (1166)
- Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death (2005) (1162)
- Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice (2011) (1141)
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. (2015) (1062)
- Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. (1999) (1025)
- Immunogenic and tolerogenic cell death (2009) (986)
- Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial (2005) (979)
- Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet? (2013) (958)
- Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines (1996) (913)
- Immunogenic death of colon cancer cells treated with oxaliplatin (2010) (877)
- Malignant effusions and immunogenic tumour-derived exosomes (2002) (863)
- Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. (2010) (837)
- CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner (2005) (836)
- Type I interferons in anticancer immunity (2015) (789)
- Immunological aspects of cancer chemotherapy (2008) (785)
- Tumor cells convert immature myeloid dendritic cells into TGF-β–secreting cells inducing CD4+CD25+ regulatory T cell proliferation (2005) (778)
- Cell death modalities: classification and pathophysiological implications (2007) (749)
- Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy (2014) (746)
- Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. (2013) (705)
- Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. (2016) (704)
- Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. (2016) (675)
- Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death (2009) (671)
- Consensus guidelines for the detection of immunogenic cell death (2014) (634)
- Natural-killer cells and dendritic cells: "l'union fait la force". (2005) (631)
- The secret ally: immunostimulation by anticancer drugs (2012) (626)
- Immune parameters affecting the efficacy of chemotherapeutic regimens (2011) (610)
- The anticancer immune response: indispensable for therapeutic success? (2008) (579)
- Decoding Cell Death Signals in Inflammation and Immunity (2010) (540)
- Inflammasomes in carcinogenesis and anticancer immune responses (2012) (538)
- Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19 (2020) (537)
- Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. (2013) (534)
- Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer (2018) (525)
- The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy (2007) (525)
- Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. (2016) (523)
- Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. (2016) (476)
- Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC (2015) (473)
- Exosomes as Potent Cell-Free Peptide-Based Vaccine. I. Dendritic Cell-Derived Exosomes Transfer Functional MHC Class I/Peptide Complexes to Dendritic Cells 1 (2004) (460)
- A novel dendritic cell subset involved in tumor immunosurveillance (2006) (448)
- The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies (2018) (444)
- Calreticulin exposure is required for the immunogenicity of γ-irradiation and UVC light-induced apoptosis (2007) (433)
- Consensus guidelines for the definition, detection and interpretation of immunogenic cell death (2020) (423)
- Molecular characteristics of immunogenic cancer cell death (2008) (417)
- Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors (2020) (412)
- Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells (2017) (410)
- In vivo veritas (2005) (393)
- Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. (2016) (361)
- Classification of current anticancer immunotherapies (2014) (357)
- An Immunosurveillance Mechanism Controls Cancer Cell Ploidy (2012) (352)
- Dendritic Cell-Derived Exosomes Promote Natural Killer Cell Activation and Proliferation: A Role for NKG2D Ligands and IL-15Rα (2009) (351)
- Autophagy and cellular immune responses. (2013) (350)
- NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. (2004) (348)
- Proteomic analysis of exosomes secreted by human mesothelioma cells. (2004) (344)
- Molecular mechanisms of ATP secretion during immunogenic cell death (2013) (341)
- Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death (2012) (339)
- Dendritic cell-derived exosomes for cancer therapy. (2016) (336)
- Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1 (2015) (333)
- Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. (2016) (332)
- Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress (2011) (327)
- Cancer and the gut microbiota: An unexpected link (2015) (326)
- Anticancer effects of the microbiome and its products (2017) (324)
- Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 (2018) (323)
- Extracellular vesicles: masters of intercellular communication and potential clinical interventions. (2016) (322)
- Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. (1995) (319)
- Targeting PD-1/PD-L1 interactions for cancer immunotherapy (2012) (316)
- Immunogenic cancer cell death: a key-lock paradigm. (2008) (315)
- The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death (2008) (312)
- Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. (2010) (312)
- Dendritic and Natural Killer Cells Cooperate in the Control/Switch of Innate Immunity (2002) (311)
- Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. (2004) (309)
- Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors (2011) (309)
- The gut microbiota influences anticancer immunosurveillance and general health (2018) (302)
- Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway (2010) (302)
- Microbiome and Anticancer Immunosurveillance (2016) (297)
- IL-18 induces PD-1-dependent immunosuppression in cancer. (2011) (296)
- Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. (2011) (293)
- Natural killer cell–directed therapies: moving from unexpected results to successful strategies (2008) (292)
- The IKK complex contributes to the induction of autophagy (2010) (290)
- Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death (2015) (287)
- Dendritic cell-derived exosomes for cancer immunotherapy: what's next? (2010) (286)
- Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. (2013) (283)
- Immunomodulatory effects of cyclophosphamide and implementations for vaccine design (2011) (278)
- Exosomes as Potent Cell-Free Peptide-Based Vaccine. II. Exosomes in CpG Adjuvants Efficiently Prime Naive Tc1 Lymphocytes Leading to Tumor Rejection 1 (2004) (276)
- The microbiome and human cancer (2021) (273)
- Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy (2011) (267)
- The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression (2006) (265)
- Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. (2013) (263)
- Trial watch: IDO inhibitors in cancer therapy (2014) (260)
- Nutrition, inflammation and cancer (2017) (246)
- Chemotherapy induces ATP release from tumor cells (2009) (246)
- Natural and therapy-induced immunosurveillance in breast cancer (2015) (245)
- Rationale for anti-OX40 cancer immunotherapy. (2016) (235)
- Mouse models in oncoimmunology (2016) (234)
- Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. (1995) (229)
- Trial Watch—Oncolytic viruses and cancer therapy (2016) (221)
- Dendritic Cell–Derived Exosomes as Immunotherapies in the Fight against Cancer (2014) (217)
- Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. (2008) (213)
- A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment. (2018) (212)
- Mucosal Imprinting of Vaccine-Induced CD8+ T Cells Is Crucial to Inhibit the Growth of Mucosal Tumors (2013) (209)
- Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy (2015) (207)
- Immunogenic cell death modalities and their impact on cancer treatment (2009) (206)
- Chemotherapy and radiotherapy: cryptic anticancer vaccines. (2010) (191)
- Ecto‐calreticulin in immunogenic chemotherapy (2007) (191)
- The role of the microbiota in inflammation, carcinogenesis, and cancer therapy (2015) (189)
- Apoptosis regulation in tetraploid cancer cells (2006) (186)
- Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy (2011) (185)
- Tumor-derived exosomes: a new source of tumor rejection antigens. (2002) (185)
- Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. (2009) (185)
- CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. (2016) (184)
- Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy (2012) (179)
- Trial watch (2013) (176)
- A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. (2015) (176)
- Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists (2013) (174)
- Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics (2017) (173)
- Prospects for exosomes in immunotherapy of cancer (2006) (172)
- Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin (1996) (170)
- Trial Watch: Monoclonal antibodies in cancer therapy (2012) (167)
- Updated Technology to Produce Highly Immunogenic Dendritic Cell-derived Exosomes of Clinical Grade: A Critical Role of Interferon-&ggr; (2011) (163)
- Bone Marrow‐Derived Dendritic Cells Serve as Potent Adjuvants for Peptide‐Based Antitumor Vaccines (1997) (162)
- Predictors of responses to immune checkpoint blockade in advanced melanoma (2017) (162)
- Cutting Edge: Crucial Role of IL-1 and IL-23 in the Innate IL-17 Response of Peripheral Lymph Node NK1.1− Invariant NKT Cells to Bacteria (2011) (156)
- Exosomes as a Tumor Vaccine: Enhancing Potency Through Direct Loading of Antigenic Peptides (2003) (156)
- Defining the critical hurdles in cancer immunotherapy (2011) (152)
- Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines1 (2006) (150)
- Trial watch (2013) (148)
- Stress–glucocorticoid–TSC22D3 axis compromises therapy-induced antitumor immunity (2019) (143)
- Interleukin‐12 and B7.1 co‐stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors (1996) (140)
- Crizotinib-induced immunogenic cell death in non-small cell lung cancer (2019) (140)
- Dendritic cell derived‐exosomes: biology and clinical implementations (2006) (140)
- Trial Watch: Toll-like receptor agonists in cancer immunotherapy (2018) (138)
- Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage (2020) (138)
- Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. (2007) (138)
- Immunogenic cell stress and death (2022) (135)
- Cyclophosphamide induces differentiation of Th17 cells in cancer patients. (2011) (132)
- Immune response against dying tumor cells. (2004) (132)
- Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. (1994) (132)
- Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. (1997) (132)
- Pyroptosis – a cell death modality of its kind? (2010) (132)
- Crosstalk between ER stress and immunogenic cell death. (2013) (130)
- Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade (2020) (127)
- Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients. (2020) (126)
- Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy (2016) (125)
- eIF2α phosphorylation is pathognomonic for immunogenic cell death (2018) (125)
- Trial watch (2012) (124)
- Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade (2019) (124)
- Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology (2020) (123)
- Immunological Mechanisms Underneath the Efficacy of Cancer Therapy (2016) (123)
- Immunological off-target effects of imatinib (2016) (120)
- Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients (2015) (118)
- Reduction of endoplasmic reticulum Ca2+ levels favors plasma membrane surface exposure of calreticulin (2008) (117)
- Prognostic impact of vitamin B6 metabolism in lung cancer. (2012) (114)
- TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. (2011) (114)
- CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. (2014) (113)
- Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer (2012) (112)
- Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. (2021) (112)
- Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications (2015) (111)
- The immunogenicity of tumor cell death (2009) (111)
- Natural killer cell–dendritic cell crosstalk in the initiation of immune responses (2005) (111)
- Exosome-based immunotherapy (2004) (110)
- NKp46 Receptor‐Mediated Interferon‐&ggr; Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis (2018) (110)
- Trial watch (2012) (110)
- Membrane-associated Hsp 72 from tumor-derived exosomes mediates STAT 3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells (2010) (109)
- Immunogenicity of anthracyclines: moving towards more personalized medicine. (2008) (109)
- Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia (2010) (108)
- CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab? (2008) (108)
- Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. (2005) (107)
- Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. (2010) (107)
- NCR3/NKp30 Contributes to Pathogenesis in Primary Sjögren’s Syndrome (2013) (107)
- Trial watch: Peptide-based vaccines in anticancer therapy (2018) (106)
- Harnessing γδ T cells in anticancer immunotherapy. (2012) (104)
- Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set (2014) (104)
- Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy (2016) (103)
- Dendritic cell-NK cell cross-talk: regulation and physiopathology. (2006) (102)
- Trial Watch: Peptide-based anticancer vaccines (2015) (102)
- Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. (2012) (101)
- Trial Watch (2013) (101)
- Selective Accumulation of Mature DC-Lamp+ Dendritic Cells in Tumor Sites Is Associated with Efficient T-Cell-Mediated Antitumor Response and Control of Metastatic Dissemination in Melanoma (2004) (101)
- Surface‐exposed calreticulin in the interaction between dying cells and phagocytes (2010) (100)
- Trial watch: STING agonists in cancer therapy (2020) (98)
- Gut microbiome and anticancer immune response: really hot Sh*t! (2014) (98)
- Cancer immunotherapy in 2017: The breakthrough of the microbiota (2018) (97)
- Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 (2015) (97)
- Dendritic Cell Maturation Overrules H-2d–Mediated Natural Killer T (Nkt) Cell Inhibition (2001) (95)
- The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer (2020) (94)
- IL‐12‐Engineered Dendritic Cells Serve as Effective Tumor Vaccine Adjuvants in Vivo a (1996) (93)
- The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer (2016) (92)
- Trial watch: Dendritic cell-based anticancer immunotherapy (2017) (91)
- Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer (2022) (91)
- Trial watch: dendritic cell vaccination for cancer immunotherapy (2019) (90)
- Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death (2012) (89)
- Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells. (1998) (88)
- Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer (2020) (87)
- Tumor stress, cell death and the ensuing immune response (2008) (87)
- Immunomodulation by targeted anticancer agents. (2020) (87)
- Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. (2011) (87)
- Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy. (2017) (86)
- Trial Watch (2012) (86)
- The Janus face of dendritic cells in cancer (2008) (85)
- Cytokine Gene Therapy of Cancer Using Interleukin‐12: Murine and Clinical Trials (1996) (84)
- Regulatory T Cells Control Dendritic Cell/NK Cell Cross-Talk in Lymph Nodes at the Steady State by Inhibiting CD4+ Self-Reactive T Cells (2008) (84)
- Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer (2015) (83)
- Exosomes for cancer immunotherapy. (2004) (83)
- The immuno-oncological challenge of COVID-19 (2020) (83)
- Trial Watch (2013) (83)
- Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. (2014) (83)
- IL-4 Confers NK Stimulatory Capacity to Murine Dendritic Cells: A Signaling Pathway Involving KARAP/DAP12-Triggering Receptor Expressed on Myeloid Cell 2 Molecules1 (2004) (82)
- Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade (2020) (82)
- Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. (2006) (82)
- The intimate relationship between gut microbiota and cancer immunotherapy (2018) (82)
- Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome. (2016) (82)
- Immune responses during COVID-19 infection (2020) (81)
- Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition (2016) (81)
- Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 (2015) (81)
- How to improve the immunogenicity of chemotherapy and radiotherapy (2011) (80)
- Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8 (2013) (80)
- The dendritic cell-tumor cross-talk in cancer. (2011) (80)
- Mature cytotoxic CD56(bright)/CD16(+) natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma. (2014) (79)
- Trial Watch (2012) (79)
- Dendritic cells (DC) promote natural killer (NK) cell functions: dynamics of the human DC/NK cell cross talk. (2002) (79)
- Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy (2011) (78)
- ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy (2013) (77)
- Lung cancer: potential targets for immunotherapy. (2013) (77)
- Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers (2021) (76)
- Trial watch (2013) (76)
- Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma (2022) (75)
- Cross-Presentation by Dendritic Cells of Tumor Antigen Expressed in Apoptotic Recombinant Canarypox Virus-Infected Dendritic Cells1 (2001) (75)
- Selective Resistance of Tetraploid Cancer Cells against DNA Damage‐Induced Apoptosis (2006) (74)
- IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. (1995) (72)
- The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? (2019) (72)
- Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy (2014) (72)
- Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens (2012) (72)
- CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. (2008) (72)
- PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade (2018) (72)
- The oncolytic peptide LTX-315 triggers immunogenic cell death (2016) (72)
- Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference (2007) (72)
- Trial Watch (2014) (72)
- STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells. (2015) (71)
- Pro-necrotic molecules impact local immunosurveillance in human breast cancer (2017) (71)
- Desirable cell death during anticancer chemotherapy (2010) (71)
- Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects. (2009) (71)
- Trial watch: Dendritic cell-based anticancer therapy (2014) (70)
- Harnessing dendritic cells in cancer. (2011) (70)
- An autophagy-dependent anticancer immune response determines the efficacy of melanoma chemotherapy (2014) (69)
- Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses (2008) (68)
- Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy? (2015) (67)
- Links between innate and cognate tumor immunity. (2007) (67)
- Viral subversion of immunogenic cell death (2009) (67)
- Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials (2016) (67)
- TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves (2018) (66)
- Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance (2017) (66)
- Oncolysis without viruses — inducing systemic anticancer immune responses with local therapies (2019) (65)
- Molecular Characterization of Dendritic Cell-Derived Exosomes (1999) (65)
- Immunosuppression by Mutated Calreticulin Released from Malignant Cells. (2019) (64)
- Dendritic cells in innate immune responses against HIV. (2002) (63)
- Interleukin‐7 (IL‐7) in Colorectal Cancer: IL‐7 is Produced by Tissues from Colorectal Cancer and Promotes Preferential Expansion of Tumour Infiltrating Lymphocytes (1997) (62)
- Dendritic cell and natural killer cell cross-talk: a pivotal role of CX3CL1 in NK cytoskeleton organization and activation. (2008) (61)
- Dendritic cells and innate defense against tumor cells. (2008) (61)
- Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer (2014) (61)
- Targeting the gut and tumor microbiota in cancer (2022) (60)
- Trial Watch: Immunotherapy plus radiation therapy for oncological indications (2016) (60)
- Viral strategies for the evasion of immunogenic cell death (2010) (60)
- Trial watch: Immune checkpoint blockers for cancer therapy (2017) (59)
- Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors (2018) (59)
- The impact of the intestinal microbiota in therapeutic responses against cancer. (2018) (59)
- Immunogenic and Non-immunogenic Cell Death in the Tumor Microenvironment. (2017) (58)
- Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39 (2012) (57)
- NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis (2018) (57)
- Trial watch (2012) (56)
- The potential of exosomes in immunotherapy (2005) (56)
- Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. (2016) (55)
- Trial Watch: Adoptively transferred cells for anticancer immunotherapy (2017) (55)
- Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients. (2002) (55)
- Trans-Presentation of IL-15 Dictates IFN-Producing Killer Dendritic Cells Effector Functions1 (2008) (54)
- Future perspectives in melanoma research (2016) (54)
- The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? (2019) (54)
- Immunosurveillance as a regulator of tissue homeostasis. (2013) (53)
- The Critical Role of IL-15 in the Antitumor Effects Mediated by the Combination Therapy Imatinib and IL-21 (2008) (53)
- Exosomes for immunotherapy of cancer. (2003) (52)
- Oral administration of Akkermansia muciniphila elevates systemic antiaging and anticancer metabolites (2021) (52)
- Trial Watch (2012) (51)
- Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer (2020) (51)
- The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1 (2018) (51)
- Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. (2004) (50)
- Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapy (2015) (50)
- The ratio of CD8+/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ (2016) (50)
- Anticancer activity of cardiac glycosides (2012) (50)
- Trial Watch: Radioimmunotherapy for oncological indications (2014) (50)
- Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers (2018) (50)
- Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy (2016) (49)
- Trial Watch: Lenalidomide-based immunochemotherapy (2013) (49)
- Dendritic cells or their exosomes are effective biotherapies of cancer. (1999) (49)
- The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade (2016) (49)
- A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice (2019) (48)
- Trial watch: TLR3 agonists in cancer therapy (2020) (48)
- acDCs enhance human antigen-specific T-cell responses. (2011) (48)
- Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress (2020) (48)
- Beneficial autoimmunity improves cancer prognosis (2021) (47)
- Dendritic cell-based immunotherapy of cancer. (2000) (47)
- Dendritic cell-derived exosomes as cell-free peptide-based vaccines. (2005) (47)
- IKK connects autophagy to major stress pathways (2010) (46)
- Killer dendritic cells: IKDC and the others. (2008) (45)
- Trial watch (2005) (45)
- Trial Watch—Immunostimulation with cytokines in cancer therapy (2016) (44)
- Trial watch: Tumor-targeting monoclonal antibodies for oncological indications (2015) (44)
- Victories and deceptions in tumor immunology (2013) (44)
- Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab (2014) (44)
- Retroviral Vectors for Use in Human Gene Therapy for Cancer, Gaucher Disease, and Arthritis a (1994) (44)
- Active specific T-cell-based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects. (1998) (44)
- Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer (2016) (44)
- Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade (2019) (44)
- Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Patients Undergoing Adjuvant Chemotherapy. (2016) (44)
- Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota (2017) (44)
- NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus (2010) (43)
- The potential of exosomes in immunotherapy of cancer. (2005) (43)
- BCR/ABL promotes dendritic cell-mediated natural killer cell activation. (2005) (43)
- NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients (2017) (42)
- Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer (2012) (42)
- Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy (2016) (41)
- Can we harness the microbiota to enhance the efficacy of cancer immunotherapy? (2020) (41)
- Trial Watch (2014) (41)
- Immunotherapy and the concept of a clinical cure. (2013) (41)
- Exosomes in cancer immunotherapy: preclinical data. (2001) (40)
- Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors (2014) (40)
- The immune response against dying tumor cells: avoid disaster, achieve cure (2008) (40)
- The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization (2015) (40)
- Disruption of the PP1/GADD34 complex induces calreticulin exposure (2009) (39)
- Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies (2015) (39)
- Murine Models of Cancer Cytokine Gene Therapy Using Interleukin‐12 a (1996) (39)
- Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment (2021) (38)
- Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy — Achieving global consensus and visibility for cellular host-directed therapies (2020) (38)
- Microbiota Modulation of Myeloid Cells in Cancer Therapy (2015) (38)
- Trial Watch (2012) (37)
- Trial Watch (2014) (37)
- Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions (2020) (37)
- Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells. (2007) (37)
- Interleukin‐12 Gene Therapy Prevents Establishment of SCC VII Squamous Cell Carcinomas, Inhibits Tumor Growth, and Elicits Long‐term Antitumor Immunity in Syngeneic C3H Mice (1998) (36)
- Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy (2018) (36)
- Harnessing the intestinal microbiome for optimal therapeutic immunomodulation. (2014) (36)
- From the antigen-presenting cell to the antigen-presenting vesicle: the exosomes. (2002) (35)
- Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy (2014) (35)
- Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering. (2014) (35)
- Cutting Edge: FcγRIII (CD16) and FcγRI (CD64) Are Responsible for Anti-Glycoprotein 75 Monoclonal Antibody TA99 Therapy for Experimental Metastatic B16 Melanoma (2012) (34)
- On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2 (2020) (34)
- Immunogenic chemotherapy: discovery of a critical protein through proteomic analyses of tumor cells. (2007) (34)
- Trial watch: dietary interventions for cancer therapy (2019) (33)
- Subversion of anticancer immunosurveillance by radiotherapy (2015) (33)
- [Immunological aspects of anticancer chemotherapy]. (2008) (33)
- CD103+ dendritic cells producing interleukin-12 in anticancer immunosurveillance. (2014) (33)
- Potent immunomodulatory effects of the trifunctional antibody catumaxomab. (2013) (33)
- Trial Watch: Adoptive cell transfer for oncological indications (2015) (32)
- Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota (2020) (32)
- Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. (2017) (32)
- Trial Watch (2013) (31)
- Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology? (2021) (31)
- Autocrine signaling of type 1 interferons in successful anticancer chemotherapy (2015) (31)
- Synthetic induction of immunogenic cell death by genetic stimulation of endoplasmic reticulum stress (2014) (31)
- Identification of pharmacological agents that induce HMGB1 release (2017) (31)
- Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications (2017) (30)
- Abscopal but desirable (2012) (30)
- Interferon-gamma is produced by another player of innate immune responses: the interferon-producing killer dendritic cell (IKDC). (2007) (30)
- The dendritic cell-like functions of IFN-producing killer dendritic cells reside in the CD11b+ subset and are licensed by tumor cells. (2009) (29)
- Trial watch: Naked and vectored DNA-based anticancer vaccines (2015) (29)
- Anticancer effects of anti-CD47 immunotherapy in vivo (2018) (29)
- Exosomes for the treatment of human malignancies. (2008) (29)
- Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer (2017) (29)
- Cancer: Antibodies regulate antitumour immunity (2015) (29)
- Trial Watch (2014) (29)
- Trial watch (2013) (29)
- Lysyl tRNA synthetase is required for the translocation of calreticulin to the cell surface in immunogenic death (2010) (28)
- Contribution of IL-17-producing gammadelta T cells to the efficacy of anticancer chemotherapy. (2020) (28)
- Natural killer cells in non-hematopoietic malignancies (2012) (27)
- Human intestinal V delta 1+ T cells obtained from patients with colon cancer respond exclusively to SEB but not to SEA. (1995) (27)
- Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis. (2016) (26)
- Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines (2013) (26)
- Can the exome and the immunome converge on the design of efficient cancer vaccines? (2012) (26)
- Phylogenetic conservation of the preapoptotic calreticulin exposure pathway from yeast to mammals (2009) (26)
- Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy (2013) (26)
- Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis (2021) (26)
- TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer (2017) (26)
- The oncolytic peptide LTX-315 triggers necrotic cell death (2015) (25)
- Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy. (2010) (25)
- Trial watch: IDO inhibitors in cancer therapy (2020) (25)
- Natural killer cell mediated immunosurveillance of pediatric neuroblastoma (2015) (25)
- An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells (2013) (24)
- Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy (2018) (24)
- Trial watch: DNA-based vaccines for oncological indications (2017) (24)
- Trial Watch (2004) (24)
- A p53-regulated immune checkpoint relevant to cancer (2015) (24)
- Trial watch (2006) (24)
- Immunoregulatory natural killer cells suppress autoimmunity by down-regulating antigen-specific CD8+ T cells in mice. (2012) (24)
- Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts (2018) (23)
- Immunologic correlates in the course of treatment with immunomodulating antibodies. (2015) (23)
- Tumor lysis with LTX-401 creates anticancer immunity (2019) (23)
- Phase I clinical trial combining imatinib mesylate and IL-2 (2013) (22)
- Anticancer effects of imatinib via immunostimulation (2011) (21)
- Death, danger, and immunity: an infernal trio (2007) (21)
- Role of interleukin-12 (IL12) as an anti-tumour agent: experimental biology and clinical application. (1995) (21)
- OncoImmunology: a new journal at the frontier between oncology and immunology (2012) (21)
- NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution (2016) (20)
- CD16+NKG2Ahigh Natural Killer Cells Infiltrate Breast Cancer–Draining Lymph Nodes (2018) (20)
- Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer (2016) (20)
- Homeostatic defects in interleukin 18‐deficient mice contribute to protection against the lethal effects of endotoxin (2011) (20)
- Interferon-γ induces cancer cell ferroptosis (2019) (19)
- Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy (2020) (19)
- Therapy-induced microenvironmental changes in cancer (2016) (19)
- Trial Watch (2013) (19)
- The oncolytic compound LTX-401 targets the Golgi apparatus (2016) (19)
- Following up tumor-specific regulatory T cells in cancer patients (2013) (18)
- Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma (2017) (18)
- Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort (2013) (18)
- Trial watch (2006) (18)
- Why should we need the gut microbiota to respond to cancer therapies? (2014) (17)
- Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer (2020) (17)
- Cancer induces a stress ileopathy depending on B-adrenergic receptors and promoting dysbiosis that contribute to carcinogenesis. (2021) (17)
- Generation of Monocyte-Derived Dendritic Cells From Patients With Renal Cell Cancer: Modulation of Their Functional Properties After Therapy With Biological Response Modifiers (IFN-&agr; plus IL-2 and IL-12) (2000) (17)
- Trial watch (2005) (17)
- Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib (2017) (16)
- Killer dendritic cells and their potential role in immunotherapy. (2008) (16)
- Immunological effects of chemotherapy in spontaneous breast cancers (2013) (16)
- Yet another pattern recognition receptor involved in the chemotherapy-induced anticancer immune response: Formyl peptide receptor-1 (2016) (16)
- Bacterial Invasion: Linking Autophagy and Innate Immunity (2010) (16)
- Contribution of annexin A1 to anticancer immunosurveillance (2019) (16)
- Immunostimulatory gut bacteria (2019) (16)
- Witch Hunt against Tumor Cells Enhanced by Dendritic Cells (2009) (16)
- CHAPTER 13 – Dendritic cell-derived exosomes (2001) (15)
- Immunosurveillance in esophageal carcinoma: The decisive impact of regulatory T cells (2016) (15)
- Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients (2015) (15)
- A TLR3 ligand reestablishes chemotherapeutic responses in the context of FPR1 deficiency. (2020) (15)
- IL‐2 production by dendritic cells is not critical for the activation of cognate and innate effectors in draining lymph nodes (2005) (15)
- Introduction: the immune response against dying cells. (2008) (15)
- Reply: Immunosuppressive cell death in cancer (2017) (14)
- The multifaceted granulysin. (2010) (14)
- Differences in the composition of the immune infiltrate in breast cancer, colorectal carcinoma, melanoma and non-small cell lung cancer: A microarray-based meta-analysis (2016) (13)
- Melanoma and immunotherapy bridge 2015 (2016) (13)
- IKDCs or B220+ NK cells are pre-mNK cells. (2012) (13)
- Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate (2016) (13)
- Positive impact of autophagy in human breast cancer cells on local immunosurveillance (2016) (13)
- T cell Bispecific Antibodies in Node-Positive Breast Cancer: Novel Therapeutic Avenue for MHC class I Loss Variants. (2019) (13)
- Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy) (2019) (12)
- Trial watch (2013) (12)
- Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals (2018) (12)
- Multifaceted modes of action of the anticancer probiotic Enterococcus hirae (2021) (12)
- Improvement of immunogenic chemotherapy by STAT3 inhibition (2016) (12)
- STAT3 inhibition for cancer therapy: Cell-autonomous effects only? (2016) (12)
- Antibiotics prescription to decrease progression-free survival (PFS) and overall survival (OS) in patients with advanced cancers treated with PD1/PDL1 immune checkpoint inhibitors. (2017) (11)
- CD4+ T Cells at the Center of Inflammaging (2020) (11)
- The dilemma of anticancer therapy: tumor-specific versus immune effects. (2008) (11)
- Trial Watch (2012) (11)
- The Ultimate Goal of Curative Anti-Cancer Therapies: Inducing an Adaptive Anti-Tumor Immune Response (2011) (11)
- Targeting dendritic cell metabolism in cancer (2010) (11)
- Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma (2021) (11)
- Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA4 immune checkpoint antibodies (2020) (11)
- Prime time for immune-checkpoint targeted therapy at ASCO 2015 (2016) (11)
- Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients (2013) (10)
- Failure of immunosurveillance accelerates aging (2019) (10)
- Trial Watch (2013) (10)
- An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpes viridae (2011) (10)
- [Exosomes and anti-tumour immunotherapy]. (2003) (10)
- Regulation of CD 4 + NKG 2 D + Th 1 cells in patients with metastatic melanoma treated with Sorafenib : role of IL-15 R α and NKG 2 D triggering (2013) (9)
- Inosine: novel microbiota-derived immunostimulatory metabolite (2020) (9)
- Effects of acyl-coenzyme A binding protein (ACBP)/diazepam-binding inhibitor (DBI) on body mass index (2021) (9)
- COVID-19: a challenge for oncology services (2020) (9)
- Trial Watch (2004) (9)
- Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer (2022) (8)
- Lower Airway Dysbiosis Exacerbates Lung Cancer. (2021) (8)
- Imatinib mesylate (Gleevec): targeted therapy against cancer with immune properties. (2010) (8)
- Recent successes of cancer immunotherapy: a new dimension in personalized medicine? (2012) (8)
- Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer (2019) (7)
- Cytokines reinstate NK cell-mediated cancer immunosurveillance. (2014) (7)
- Trial Watch: (2013) (7)
- Author Correction: Crizotinib-induced immunogenic cell death in non-small cell lung cancer (2019) (7)
- Trial watch (2004) (7)
- CD16 + NKG2A high natural killer cells infiltrate breast cancer draining lymph nodes (2018) (7)
- Harnessing the microbiome to restore immunotherapy response (2021) (7)
- A fluorescent biosensor-based platform for the discovery of immunogenic cancer cell death inducers (2019) (7)
- Immune infiltrate in cancer (2015) (7)
- Science-Driven Nutritional Interventions for the Prevention and Treatment of Cancer. (2022) (7)
- Immunodynamics of explanted human tumors for immuno‐oncology (2020) (6)
- Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting (2013) (6)
- Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers (2022) (6)
- [Calreticulin dictates the immunogenicity of anti-cancer chemotherapy and radiotherapy]. (2007) (6)
- Seeking Cellular Fitness and Immune Evasion: Autophagy in Pancreatic Carcinoma. (2020) (6)
- Gut microbiome composition to predict resistance in renal cell carcinoma (RCC) patients on nivolumab. (2018) (6)
- The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals (2022) (6)
- Microenvironment and Immunology Natural Killer Cells Are Essential for the Ability of BRAF Inhibitors to Control BRAFV 600 E-Mutant Metastatic Melanoma (2014) (6)
- Cross-reactivity between cancer and microbial antigens (2021) (6)
- The immune system: taming and unleashing cancer. (2006) (6)
- Gut microbiome to predict efficacy and immune-related toxicities in patients with advanced non-small cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy. (2020) (6)
- [The role of intestinal microbiota in the response to anti-tumor therapies]. (2016) (6)
- Impact of the ileal microbiota on colon cancer. (2021) (6)
- Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors (2020) (6)
- A novel mode of antitumor activity for imatinib mesylate: Consequences for the design of surrogate markers of efficacy and combination therapies (2005) (5)
- Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses (2020) (5)
- Reply: The complement system is also important in immunogenic cell death (2016) (5)
- Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patients (2020) (5)
- [Gut microbiota and efficacy of cancer therapies]. (2017) (5)
- Subversion of calreticulin exposure as a strategy of immune escape. (2021) (5)
- Phase I/II study of the association of sorafenib and temozolomide (extended schedule) in patients with metastatic melanoma: A new clinical response profile with massive tumor necroses. (2009) (5)
- Cell-death-associated molecular patterns as determinants of cancer immunogenicity. (2014) (5)
- [Antitumoral immunization during cancer chemotherapy]. (2012) (5)
- Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy (2022) (5)
- In vivo depletion of T lymphocyte-specific transcription factors by RNA interference (2010) (5)
- Trial Watch (2012) (5)
- Escherichia coli-specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer. (2022) (5)
- B7.1 EXPRESSION ENHANCES EFFECTIVE IL-12 MEDIATED ANTITUMOR IMMUNITY (1994) (4)
- Leptin-Producing Oncolytic Virus Makes Tumor-Infiltrating T Cells Fit, Not Fat. (2019) (4)
- CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 Immunotherapy (2021) (4)
- Reply to: Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system (2012) (4)
- The Porto European Cancer Research Summit 2021 (2021) (4)
- Pegylated Engineered IL2 plus Anti-PD-1 Monoclonal Antibody: The Nectar Comes from the Combination. (2020) (4)
- BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer (2022) (4)
- Targeting Toll like receptor 3 by double stranded RNA in breast cancer: Results from in vitro studies and randomized trial. (2004) (4)
- Reply to ‘Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma’ (2018) (4)
- [Innate defence against tumor cells: the killer cell IKDC]. (2006) (4)
- Bortezomib Induces Immunogenic Cell Death in Multiple Myeloma. (2021) (4)
- Cross-reactivity between microbial and tumor antigens. (2022) (4)
- Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas (2019) (4)
- Targeting foxp1 for reinstating anticancer immunosurveillance. (2014) (3)
- Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts (2017) (3)
- PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer (2022) (3)
- Immunogenic Stress and Death of Cancer Cells in Natural and Therapy-Induced Immunosurveillance (2018) (3)
- A probiotic supplement boosts response to cancer immunotherapy (2022) (3)
- Bacteria-specific CXCL13-producing follicular helper T cells are putative prognostic markers to neoadjuvant PD-1 blockade in muscle-invasive urothelial carcinoma. (2022) (3)
- Modulation of cancer immunotherapy by dietary fibers and over-the-counter probiotics. (2022) (3)
- Abstract CT221: Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC) (2019) (3)
- Targeting Toll like receptor 3 by double stranded RNA in breast cancer: Results from in vitro studies and randomized trial (2004) (3)
- Intestinal Akkermansia muciniphila predicts overall survival in advanced non-small cell lung cancer patients treated with anti-PD-1 antibodies: Results a phase II study. (2021) (3)
- [IKDC: killer dendritic cells or antigen-presenting NK cells?]. (2008) (3)
- [NK cell-based immunotherapy: new prospects and involvement of dendritic cells]. (2003) (3)
- The TLR4 polymorphism predicts the response of breast cancer patients to anthracyclins (2007) (3)
- IL-18 Elicited Suppressor NK Cells with Immunoregulatory Functions (2008) (3)
- Fecal microbiota transplantation: can it circumvent resistance to PD-1 blockade in melanoma? (2021) (3)
- Dendritic and tumour cell -derived exosomes as novel cancer vaccines (1999) (2)
- Toll like receptor 3 expression and efficacy of adjuvant treatment with polyadenylic-polyuridylic acid in patients with axillary node positive breast cancer: Results from two randomized trials. (2006) (2)
- Dendritic Cells and Natural Killer Cells (2008) (2)
- [Contributions of immunogenic cell death to the efficacy of anticancer chemotherapy]. (2011) (2)
- Microbiota Modulation of Myeloid Cells in Cancer (2015) (2)
- Laurie Menger Cell Death Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic (2012) (2)
- Bodywide ecological interventions on cancer (2023) (2)
- A genotype-phenotype screening system using conditionally immortalized immature dendritic cells (2021) (2)
- Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC). (2018) (2)
- RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies (2023) (2)
- Boosting the immunotherapy response by nutritional interventions (2022) (2)
- 277 Safety and efficacy of intratumoral ipilimumab with IV nivolumab in metastatic melanoma. The NIVIPIT trial (2021) (2)
- Guidelines for DC preparation and flow cytometry analysis of mouse nonlymphoid tissues. (2022) (2)
- Cancer is not just a disease of a tissue: it is a host disease. How to reactivate host defense against tumors using conventional therapies of cancer? (2008) (2)
- Antibiotics impair immunotherapy for urothelial cancer (2020) (2)
- PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade (2018) (2)
- Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer (2020) (2)
- Circulating acetylated polyamines correlate with Covid-19 severity in cancer patients (2021) (2)
- Interactions Between NK Cells and Regulatory T Cells (2010) (2)
- The dialogue between natural killer cells and dendritic cells (2005) (2)
- The oncolytic compound LTX-401 targets the Golgi apparatus (2017) (2)
- Mutanome Engineered RNA Immunotherapy (MERIT). (2015) (2)
- Tumoral Immune Cell Exp loitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR 5 Therapy in Cancer Patients Graphical (2016) (2)
- Cutting Edge : Fc gamma RIII (CD16) and Fc gamma RI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma (vol 189, pg 5513, 2012) (2013) (2)
- [Role of dendritic cells in the modulation of innate effectors of immunity]. (2001) (1)
- Luxibacter massiliensis gen. nov., sp. nov., a new bacterium isolated from the human gut microbiota (2021) (1)
- Predictive value of MRP2, p53, bcl2 and topoisomerase II immunostainings for the efficacy of anthracyclines-based adjuvant chemotherapy in breast cancer: Results from two randomized trials (2008) (1)
- Antitumor effects of Flt3L in poorly immunogenic mouse tumor models (1997) (1)
- Antibody co-targeting of DCs. (2011) (1)
- [Antitumor cellular immunotherapy: the breakthrough of dendritic cells]. (2000) (1)
- Effect of CTLA-4 blockade on lymphocyte resistance to regulatory T cells in advanced melanoma and use as a surrogate marker of efficacy of tremelimumab (2008) (1)
- [A bacteriophage from the intestinal microbiota induces an anti-tumoral response by a cross-reactivity mechanism]. (2021) (1)
- Metronomic cyclophosphamide regimen electively depletes CD4+ CD25+ regulatory T cells in patients with advanced solid tumors. (2006) (1)
- 99TiPMutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (2017) (1)
- PRODIGE67_UCGI33 ARION: Association of radiochemotherapy and immunotherapy for the treatment of unresectable oesophageal cancer: A comparative randomized phase II trial (2019) (1)
- [A new dendritic cell implicated in antitumoral immunity]. (2006) (1)
- The fabulous legacy of a Nobel Prize Laureate (2012) (1)
- Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting. (2018) (1)
- Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti–PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma (2023) (1)
- P62.01 PREVALUNG: Evaluation of Lung Cancer Prevalence in Patients With Smocking-associated Atherosclerotic Cardiovascular Diseases (2021) (1)
- Trial watch (2004) (1)
- Publisher Correction: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer (2020) (1)
- Microenvironment and Immunology CCL 2 / CCR 2-Dependent Recruitment of Functional Antigen-Presenting Cells into Tumors upon Chemotherapy (2014) (1)
- Studies Immune In fi ltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors (2013) (1)
- CANCER GENE THERAPY USING INTERLEUKIN-12 (IL-12) (1994) (1)
- Abstract 2352: Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allow their intratumoral delivery and an improved tumor-growth inhibition (2016) (1)
- Combining Immunotherapies with Standard Therapies in the Treatment of Cancer (2016) (1)
- Ghrelin and leptin regulating wound healing. (2022) (1)
- Erratum: The oncolytic compound LTX-401 targets the Golgi apparatus. (2018) (1)
- Turning tolerogenic into immunogenic ileal cell death through ileal microbiota: the key to unlock the mystery of colon cancer immunoscore? (2020) (1)
- [Vaccine strategies against melanoma]. (2006) (1)
- Abstract 4563: Local and abscopal effects in oncolytic virotherapy are boosted by immune checkpoint blockade, immunogenic chemotherapy, or IFNAR blockade (2017) (1)
- Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy (2022) (1)
- Abstract CT201: The Mutanome Engineered RNA Immuno-Therapy (MERIT) project (2015) (1)
- Epidemiological Study to Assess the Prevalence of Lung Cancer in patients with smoking-associated atherosclerotic cardiovascular diseases: PREVALUNG study protocol (2019) (1)
- Abstract CT020: MERIT: introducing individualized cancer vaccines for the treatment of TNBC - a phase I trial (2016) (1)
- Melanoma TA 99 Therapy for Experimental Metastatic Anti-Glycoprotein 75 Monoclonal Antibody ( CD 64 ) Are Responsible for RI γ RIII ( CD 16 ) and Fc γ Cutting Edge : Fc (2012) (1)
- Prior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients (2019) (1)
- A pharyngeal jaw evolutionary innovation facilitated extinction in Lake Victoria cichlids (2015) (1)
- Therapy-induced microenvironmental changes in cancer (2016) (0)
- 353 INVITED Immunotherapy of Paediatric Malignancies (2011) (0)
- Exosome-based cancer vaccines (2005) (0)
- Effector IFN-Producing Killer Dendritic Cells -Presentation of IL-15 Dictates Trans (0)
- From the editors (2006) (0)
- PD-1-based immunotherapy affected by gut microbiome PD-1-based immunotherapy affected by gut microbiome (2022) (0)
- CD4 regulatory T cells inhibit natural killer cell functions in a transforming growth factor– (cid:1) –dependent manner (2005) (0)
- Abstract 66: BCG can subvert patients antitumor immune response by downregulating HLA-I expression on cancer cells (2021) (0)
- The NKp30/B7H6 Axis Contributes To Pathogenesis In Primary Sjogren's Syndrome. (2013) (0)
- Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers (2022) (0)
- EFFICIENT EXPRESSION OF IL12 AFTER TRANSDUCTION OF TUMOR CELLS WITH A RETROVIRAL VECTOR ENCODING BOTH SUBUNITS OF HUMAN IL12 (1993) (0)
- Modes of action of ipilimumab and biomarkers of resistance to therapy in patients (2013) (0)
- Commensals shape the immune system (2021) (0)
- the Steady State by Inhibiting CD4+ Cell/NK Cell Cross-Talk in Lymph Nodes at Regulatory T Cells Control Dendritic (2013) (0)
- The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups and correlates with gut microbiota (GM) in patients with advanced renal cell carcinoma (RCC). (2023) (0)
- Trial Watch (2013) (0)
- Anticancer effects of polyadenylic-polyuridylic acid (poly[A:U]) and uncoupling of chemokine receptor signaling: Role of CCR5 and CXCR3. (2009) (0)
- Is an anticancer immune response mandatory for therapeutic success (2008) (0)
- Trial Watch (2012) (0)
- Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy) (2022) (0)
- Molecules Receptor Expressed on Myeloid Cell 2 Involving KARAP / DAP 12-Triggering PathwayMurine Dendritic Cells : A Signaling IL-4 Confers NK Stimulatory Capacity to (2004) (0)
- Author Correction: Crizotinib-induced immunogenic cell death in non-small cell lung cancer (2019) (0)
- [Chemokine receptors expression on T cells: contribution to diagnosis of melanoma metastasis dissemination status]. (2016) (0)
- Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy) (2022) (0)
- Abstract 4928: Impact ofE. hiraeon the tumoricidal activity of cyclophosphamide (2017) (0)
- The seventh author was omitted from the article. An affiliation was also omitted from the article. The corrected author and affiliation lines are below. (2013) (0)
- Interferon-γ induces cancer cell ferroptosis (2019) (0)
- Anticancer effect obtained against MCA205 sarcoma following treatment with the oncolytic peptide LTX-315 in combination with immune checkpoint inhibitors (2015) (0)
- Vogels Pathways and Memory Networks Inhibitory Plasticity Balances Excitation and Inhibition in Sensory (2012) (0)
- Immunopharmacology of cancer vaccines: Restoration of NKG2D levels and functions in metastatic melanoma treated with exosomes. (2006) (0)
- Crizotinib-induced immunogenic cell death in non-small cell lung cancer (2019) (0)
- Melanoma and immunotherapy bridge 2015 (2016) (0)
- Abstract CT108: A phase I dose escalation study of intra-tumoral LTX-315 as monotherapy or in combination with either ipilimumab or pembrolizumab in patients with transdermally accessible tumors (NCT01986426) (2017) (0)
- Abstract B037: Macrophage repolarization therapy in metastatic colorectal cancer: CCR5 inhibition (2016) (0)
- PHASE I CLINICAL TRIAL OF INTERLEUKIN-12 (IL-12) CYTOKINE GENE THERAPY WITH OBJECTIVE RESPONSES IN CANCER PATIENTS WITH VARIOUS HISTOLOGIES (1997) (0)
- CANCER GENE THERAPY USING IL-4, IL-12 OR IL-15 WITH THE COSTIMULATORY MOLECULES CD27, CD30, CD40 OR B7.1 (1995) (0)
- Correction: Cutting Edge: FcγRIII (CD16) and FcγRI (CD64) Are Responsible for Anti-Glycoprotein 75 Monoclonal Antibody TA99 Therapy for Experimental Metastatic B16 Melanoma (2013) (0)
- Traitement ameliore du cancer par arn double brin (2004) (0)
- Cellular vesicle called "exosome", its preparation and use in the stimulation of an immune response (1998) (0)
- An immunosurveillance mechanism controls cancer cell ploidy. Supplementary Material. (2013) (0)
- Identification of pharmacological agents that induce HMGB1 release (2017) (0)
- A cellular vesicles 'exosome', its preparation and use for stimulating an immune Antworts (1998) (0)
- Clinical Studies Immune In fi ltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors (2013) (0)
- 1452MO Longitudinal analysis reveals gut microbiota shift during standard therapies in metastatic renal cell carcinoma (mRCC) (2022) (0)
- Impact of microbiota on breast cancer hormone therapy (2023) (0)
- The Dendritic Cell: The Immune System's Adjuvant-A Strategy To Develop a HCV Vaccine? (2006) (0)
- Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts (2017) (0)
- Genetic risk factors in non-BRCA breast/ovarian cancer families. (2008) (0)
- Langerhans islets induce anti-tumor immunity at the expense of glycemic control and predict chemotherapy response in pancreatic cancer (2021) (0)
- Unchaining NK cell–mediated anticancer immunosurveillance (2016) (0)
- Immune checkpoint inhibitors (2021) (0)
- Defective Immunity Against SARS-CoV-2 Omicron Variants Despite Full Vaccination in Hematologic Malignancies. (2023) (0)
- Death, danger, and immunity (2007) (0)
- Natural nanoparticules against cancer: mature dendritic cell-derived exosomes (2011) (0)
- Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab (2014) (0)
- Self-Reactive T Cells + the Steady State by Inhibiting CD 4 Cell / NK Cell Cross-Talk in Lymph Nodes at Regulatory T Cells Control Dendritic (2008) (0)
- Future perspectives in melanoma research (2016) (0)
- Comment on Tacken et al , page 6836 Antibody co-targeting of DCs---------------------------------------------------------------------------------------------------------------- (2011) (0)
- biosis and cohabitation / Symbiose et cohabitation e impact of the intestinal microbiota in therapeutic sponses against cancer § , § § pact du microbiote intestinal dans les réponses aux thérapies contre cancer (2018) (0)
- Anticancer action of caloric restrictions via microbiota (2023) (0)
- The European Academy of Tumor Immunology (2012) (0)
- Immature neutrophils and high anti-SARS-CoV-2 IgG levels are hallmarks of severe and 1 critical COVID-19 infection 2 3 (2020) (0)
- Abstract SY28-03: Targeting tetraploidy for cancer therapy by pharmacological and immunological strategies. (2013) (0)
- Principles of Oncoimmunology (2018) (0)
- Cellular vesicles 'exosome', its manufacture and use for stimulation of an immune response (1998) (0)
- Immunogenicity of Cytotoxic Drugs: Molecular Bases and Clinical Implementation (2007) (0)
- Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies and use of microbial modulators for improving the efficacy of an anti-pd1/pd-l1/pd-l2 ab-based treatment (2017) (0)
- Personalized immunotherapy: a siren myth? (2009) (0)
- OR.91. The Critical Role of IKDC in the Antitumor Effects Mediated by the Combination Therapy with Imatinib and IL-2 (2008) (0)
- Complexes to Dendritic Cells Transfer Functional MHC Class I/Peptide Vaccine. I. Dendritic Cell-Derived Exosomes Exosomes as Potent Cell-Free Peptide-Based (2004) (0)
- in NK cytoskeleton organization and activation Dendritic cell and natural killer cell cross-talk: a pivotal role of CX3CL1 (2013) (0)
- Abstract 5128: Induction of immunogenic cell death and tumor regression in murine animal models by a novel cytolytic compound, LTX-401 (2017) (0)
- Gist natural killers (2011) (0)
- Molecular basis of the immunogenicity of cell death during chemotherapy (2008) (0)
- Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy) (2019) (0)
- Tumor Rejection Efficiently Prime Naive Tc 1 Lymphocytes Vaccine . II . Exosomes in CpG Adjuvants Exosomes as Potent Cell-Free Peptide-Based Angevin and (2004) (0)
- Double-stranded RNA in Breast Cancer TLR 3 as a Biomarker for the Therapeutic Efficacy of (2011) (0)
- IL-12: basic concepts and role in hematopoiesis (1996) (0)
- Author Correction: The immuno-oncological challenge of COVID-19 (2022) (0)
- 3350 Mx1 incomplete loss in primary ulcerated melanoma: An observation that may help explain IFNa sensitivity of ulcerated melanoma? (2015) (0)
- Predictors of responses to immune checkpoint blockade in advanced melanoma (2017) (0)
- 259MO A predictive score of cancer immunotherapy responses based on ecological analysis of gut microbiota (2022) (0)
- The polarity and specificity of SARS-CoV2 -specific T lymphocyte responses determine disease susceptibility (2021) (0)
- Prolonged SARS-CoV-2 RNA virus shedding and 1 lymphopenia are hallmarks of COVID-19 in cancer 2 patients with poor prognosis 3 4 (2021) (0)
- Dendritic Cells Recombinant Canarypox Virus-Infected Tumor Antigen Expressed in Apoptotic Cross-Presentation by Dendritic Cells of (2001) (0)
- Bortezomib Induces Immunogenic Cell Death in Multiple Myeloma. (2021) (0)
- Abstract IA22: The unsuspected role of gut microbiota in cancer therapies: Antigen mimicry between intestinal phage and tumor antigens (2020) (0)
- Methods of activating natural killer (NK) cells and means of implementation (1998) (0)
- OR.13. Endogenous Danger Signals from Dying Tumor Cells Promote T-cell-dependent Antitumor Responses Which Determine the Efficacy of Conventional Anticancer Therapies (2008) (0)
- 24 INVITED Novel ideas in DC therapy and DC crosstalk (2006) (0)
- L4.3 No Cure without Immune Responses in Cancer Treated with Cytotoxic Agents (2012) (0)
- Immune surveillance and tumor immunity (SY2-5) Chairpersons: Takashi Nishimura, Laurence Zitvogel (2010) (0)
- Based Vaccines Cyclophosphamide Synergizes with Exosome Chemoimmunotherapy of Tumors: (2006) (0)
- Introduction to the Special Issue: Nutrition, microbiota and immunity. (2023) (0)
- FRI0179 anti-TNF Therapy Is Associated with An Impaired Function of Nk Cells and A Defective Immunosurveillance against B-Cell Lymphomas (2016) (0)
- Positive and Negative Impact of Immune Cells on Disease Outcome in Cancer Patients Treated with Chemotherapy Cells Markers Cancer Type (2015) (0)
- Abstract 2326: LTX-315, an oncolytic peptide, increases anticancer immunity mediated by CTLA4 blockade in an interleukin-2 receptor beta-chain-dependent manner (2016) (0)
- Light shed from the gut in large B-cell lymphoma. (2023) (0)
- Abstract 3021: CCR5 inhibition: macrophage repolarization therapy for colorectal cancer (2017) (0)
- Erratum to Martins I, et al. Cell Cycle Volume 8, Issue 22; pp. 3723–8 (2012) (0)
- Abstract IA17: Gut microbiota controls immuneresponses during cancer therapy (2016) (0)
- New cell sensitization process and antigen presenting new ways to implement PROCESS (1997) (0)
- 1773P Anti-PD1-induced acute interstitial pneumonitis is characterized by alveolar infiltration of PD-1+CD38+TIGIT+ cytotoxic effector CD8+ T cells and CD206+ inflammatory macrophages (2021) (0)
- Abstract SY03-01: The desirable death of the cancer cell: Immunogenic cell death for optimal chemotherapy (2010) (0)
- Contribution of Immunogenic Cell Death (ICD) to the Anti-Tumor Activity of Catumaxomab (ANTI-EPCAM X ANTI-CD3) (2012) (0)
- Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade (2019) (0)
- Tumor-infiltrating lymphocytes for melanoma immunotherapy (2023) (0)
- 901 Bacillus Calmette-Guerin can subvert patients antitumor immune response by downregulating HLA-I expression on cancer cells (2021) (0)
- Combining tumor destruction by electrochemotherapy and innate immunity by CpG-ODN: Toward a new combination treatment for melanoma with skin metastases. (2006) (0)
- Molecular and Metabolic Cues of the Key-Lock Paradigm Dictating Immunogenic Cell Death (2014) (0)
- A novel dendritic cell subset supporting the concept of tumor immunoediting: IFN producing Killer Dendritic cell (IKDC) (2006) (0)
- IL-18-elicited regulatory NK cells with immunoablative functions (40.22) (2009) (0)
- Science Magazine (2006) (0)
- Sophie Viaud of Cyclophosphamide The Intestinal Microbiota Modulates the Anticancer Immune Effects (2013) (0)
- [About Ralph M. Steinman and dendritic cells]. (2011) (0)
- Evidence of Abundant Purifying Selection in Humans for Recently Acquired Regulatory Functions (2012) (0)
- Immune system and intestinal microbiota determine efficacy of androgen depletion therapy against prostate cancer. (2022) (0)
- Intratumor (IT) gene transfer with recombinant adenovlral (rAd) vectors in lung cancer (LC) patients (PTS): The institut Gustave Roussy (IGR) experience (1997) (0)
- Immune-checkpoint inhibitors (2020) (0)
- CHAPTER 18 – NK cells (2001) (0)
- Sandoval the Growth of Mucosal Tumors T Cells Is Crucial to Inhibit + Mucosal Imprinting of Vaccine-Induced CD 8 (2013) (0)
- Dysfunction Toll-like receptor 4 and biological applications thereof (2007) (0)
- cell vesicle called "exosome", its preparation and its use in stimulating an immune response. (1998) (0)
- Reply to ‘Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma’ (2018) (0)
- Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals (2018) (0)
- Genetically-modified dendritic cells serve as effective adjuvants in promoting antitumor immunity in vitro and in vivo (1996) (0)
- Abstract CN2-1: Personalized chemotherapy of cancer based on immune parameters (2010) (0)
- eIF2α phosphorylation is pathognomonic for immunogenic cell death (2018) (0)
This paper list is powered by the following services:
Other Resources About Laurence Zitvogel
What Schools Are Affiliated With Laurence Zitvogel?
Laurence Zitvogel is affiliated with the following schools:
